好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Head CT Scan can Distinguish Tumefactive Demyelinating Lesions From Glioblastoma Multiforme
Multiple Sclerosis
P9 - Poster Session 9 (5:00 PM-6:00 PM)
19-009

To investigate the utility of computed tomography (CT) head in distinguishing between tumefactive demyelinating lesions (TDL) and glioblastoma, IDH-wildtype (GBM).

 

TDL is challenging to diagnose, often mimicking high-grade glioma and potentially leading to unnecessary invasive procedures and delayed treatment. As patients typically present acutely, CT head is commonly obtained in the emergent setting, offering complementary diagnostic information to brain MRI.
This was a single center retrospective cross-sectional study of patients with TDL and GBM, with both MRI and CT head available within one week of each other. MRI included T1, T2/FLAIR, DWI, SWI and T1 enhanced sequences. The primary outcome was lesion attenuation pattern on CT head. Secondary outcomes included MRI enhancement characteristics, lesion number, and anatomical distribution. An expert neuroradiologist, blinded to the final diagnosis, performed the MRI and CT analysis.

A total of 77 patients were included: 39 TDL and 38 GBM.

TDL lesions were more likely to be isodense or hypodense on CT compared with normal brain than GBM (35/39, 90% vs. 9/38, 24%, p<0.001). TDL patients were more likely to have multiple enhancing lesions on post-gadolinium T1 sequences than GBM patients (19/39, 49% vs 10/38, 26% p=0.025). TDL lesions were more likely to be located in the frontal lobe (22/39, 56% vs 10/38, 26%, p=0.007).

CT imaging provides a valuable, low-cost diagnostic tool for differentiating TDL from GBM, with isodense or hypodense lesions on CT head being more frequent with patients with TDL.

Authors/Disclosures
Federico Montini, MD, PhD (Mayo Clinic College of Medicine and Science)
PRESENTER 		Mr. Montini has nothing to disclose.
Pearse Morris, kjsdfkshd Ms. Morris has nothing to disclose.
Paul Decker (Mayo Clinic) Paul Decker has nothing to disclose.
Nabeela Nathoo, MD, PhD Dr. Nathoo has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis.
Yalda Nikanpour, MD Dr. Nikanpour has nothing to disclose.
Jeanette Eckel-Passow The institution of Jeanette Eckel-Passow has received research support from NIH.
W. O. Tobin, PhD, MBBCh, BAO, FAAN (Mayo Clinic) The institution of Dr. Tobin has received research support from Merck. The institution of Dr. Tobin has received research support from National Institutes of Health. Dr. Tobin has received publishing royalties from a publication relating to health care. Dr. Tobin has received personal compensation in the range of $0-$499 for serving as a Paid consulting and advisory activities with Mayo Clinic Platform_Accelerate.